IDYA NASDAQ
IDEAYA Biosciences, Inc.
1W: -5.3%
1M: -12.3%
3M: -5.9%
YTD: -1.0%
1Y: +14.8%
3Y: +32.5%
5Y: +46.5%
$33.50
+0.62 (+1.89%)
Weekly Expected Move ±5.7%
$31
$33
$35
$37
$39
Credit Risk of going bust: lower than 86% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99.9%), IDEAYA Biosciences, Inc. would be worth roughly what it owes.
Total debt $29.3M against a stock market value of $3.23B.
Distance to default 11.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $14.7M (short-term plus half of long-term), stock volatility 45.4%; Altman Z'' 11.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 99.9%), IDEAYA Biosciences, Inc. would be worth roughly what it owes.
Total debt $29.3M against a stock market value of $3.23B.
Distance to default 11.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $14.7M (short-term plus half of long-term), stock volatility 45.4%; Altman Z'' 11.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (64)
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell?
IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma
IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock
What's next for personalized mRNA cancer vaccines?
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of “Moderate Buy” from Analysts
IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bank of America Corp DE Buys New Stake in IDEAYA Biosciences, Inc. $IDYA
Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA
Allianz Asset Management GmbH Purchases Shares of 20,000 IDEAYA Biosciences, Inc. $IDYA
Bank of New York Mellon Corp Takes Position in IDEAYA Biosciences, Inc. $IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biotech Breakout: What's in focus after Moderna's cancer win?
IDEAYA Biosciences GAAP EPS of -$1.22 misses by $0.14, revenue of $8.86M beats by $1.41M
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Biggest stock movers Tuesday: APLD, QCOM, and more
IDEAYA Biosciences prices $300M public offering of shares and pre-funded warrants at $27/share
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
12 Health Care Stocks Moving In Monday's After-Market Session
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Earnings Scheduled For May 5, 2026
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences GAAP EPS of -$1.11 misses by $0.12, revenue of $6.56M beats by $1.52M
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout
Top Quant rated communications equipment stocks as Nokia Oyj surges
Biggest stock movers Monday: REPL, GS, LEG and more
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars
Stock Market Today: Dow Futures Fall As Trump Announces Strait Of Hormuz Blockade—Goldman Sachs, Fastenal In Focus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
12 Health Care Stocks Moving In Friday's After-Market Session
IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Stock Traders Purchase High Volume of IDEAYA Biosciences Put Options (NASDAQ:IDYA)
IDEAYA slips on delaying results from darovasertib uveal melanoma trial
Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $48.69
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up Following Insider Buying Activity
IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
General American Investors Co. Inc. Raises Stock Position in IDEAYA Biosciences, Inc. $IDYA
IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
IDEAYA Biosciences, Inc. $IDYA Stock Position Reduced by Fisher Asset Management LLC
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away
Creative Planning Boosts Stake in IDEAYA Biosciences, Inc. $IDYA
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events